Stocks
Ascentage Pharma Group InternatAAPG
NASDAQHealthcareBiotechnology$14.92
Price as of · delayed, not real-time
A clinical-stage biopharmaceutical company developing apoptosis-targeted therapies for cancer and other diseases. Its lead candidate, olverembatinib, is approved in China for certain leukemias, and the company is advancing a pipeline of novel drug candidates. Investors track it for its China-focused commercial launch and global development potential.
52W Range: $14.46-$35.46
Congressional Interest in Ascentage Pharma Group Internat (AAPG)
No congressional trades have been disclosed for Ascentage Pharma Group Internat (AAPG) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
0
Unique Politicians
0
Buys
0
Sells
0
Who in Congress Is Trading AAPG?
No congressional trades found for this stock.